Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma

J Pediatr Hematol Oncol. 2021 Mar 1;43(2):e165-e168. doi: 10.1097/MPH.0000000000001720.

Abstract

Secondary expansion and/or evolution of aggressive subclones are associated with the disease progression and resistance to chemotherapy in neuroblastoma, and it is important to track the clonal changes during the treatment period. Cell-free (cf) DNA analysis, namely liquid biopsy, can detect the genomic change of tumor cells without surgical procedures. In this report, we showed that serial polymerase chain reaction-based cf DNA neuroblastoma proto-oncogene quantification is sensitive enough to evaluate the aggressive cellular characteristics of ALK/MYCN-coamplified neuroblastoma and stressed the promise of cf DNA analyses as a reliable molecular marker in advanced neuroblastoma.

Publication types

  • Case Reports

MeSH terms

  • Anaplastic Lymphoma Kinase / genetics*
  • Biomarkers, Tumor / genetics*
  • Cell-Free Nucleic Acids / analysis*
  • Cell-Free Nucleic Acids / genetics
  • DNA Copy Number Variations*
  • Gene Amplification*
  • Humans
  • Infant
  • Male
  • N-Myc Proto-Oncogene Protein / genetics*
  • Neuroblastoma / diagnosis*
  • Neuroblastoma / genetics
  • Prognosis
  • Proto-Oncogene Mas

Substances

  • Biomarkers, Tumor
  • Cell-Free Nucleic Acids
  • MAS1 protein, human
  • MYCN protein, human
  • N-Myc Proto-Oncogene Protein
  • Proto-Oncogene Mas
  • ALK protein, human
  • Anaplastic Lymphoma Kinase